TVRD Tvardi Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1346830 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.7%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-123.1%
ROA-85.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets34.3%
Debt / equity0.00x
Current ratio2.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $7.14M | $20.97M | $41.87M | $23.03M |
| Cost of revenue | — | — | — | — | $0 |
| Gross profit | — | — | — | — | $23.03M |
| R&D expense | $18.01M | $23.65M | $108.51M | $91.88M | $82.70M |
| SG&A expense | $8.74M | $4.46M | $27.78M | $30.26M | $29.41M |
| Operating income | -$26.75M | -$28.11M | -$121.50M | -$87.53M | -$89.08M |
| Pretax income | — | -$71.27M | -$118.51M | -$85.47M | -$88.44M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.21M | -$29.40M | -$118.51M | -$85.47M | -$88.44M |
| EBITDA | -$26.65M | -$28.01M | -$121.24M | -$87.29M | -$88.83M |
| EPS (basic) | -2.46 | -11.42 | -26.26 | -19.12 | -1.74 |
| EPS (diluted) | -3.26 | -11.42 | -26.26 | -19.12 | -1.74 |
| Dividends declared per share | 0.00 | — | — | — | — |
| Weighted avg. shares (diluted) | 7.78M | 2.57M | 4.51M | 4.47M | 50.72M |
| Balance sheet | |||||
| Cash & equivalents | $20.73M | $31.61M | $22.92M | $64.15M | $13.86M |
| Short-term investments | $10.08M | — | — | — | $153.58M |
| Receivables | — | $407,000 | $2.77M | $3.26M | — |
| Inventory | — | $900,000 | $2.82M | $2.38M | $2.58M |
| Current assets | $31.54M | $31.69M | $116.16M | $168.91M | $173.29M |
| PP&E, net | $52,000 | $84,000 | $3.32M | $426,000 | $631,000 |
| Intangibles | $322,000 | $385,000 | — | — | — |
| Total assets | $32.07M | $35.20M | $125.84M | $182.24M | $247.06M |
| Current liabilities | $11.04M | $10.37M | $25.59M | $23.46M | $17.62M |
| Total liabilities | $11.13M | $40.83M | $68.76M | $23.46M | $19.53M |
| Shareholders' equity | $20.95M | -$91.13M | -$62.06M | $158.78M | $227.52M |
| Shares outstanding | 9.38M | 2.57M | 4.54M | 53.80M | 53.48M |
| Cash flow statement | |||||
| Operating cash flow | -$23.50M | -$18.30M | -$92.08M | -$78.73M | -$60.09M |
| Capital expenditure | — | $1.05M | $2.38M | $43,000 | $39,000 |
| Free cash flow | — | -$19.35M | -$94.45M | -$78.77M | -$60.13M |
| Investing cash flow | -$10.08M | $48.74M | $43.46M | $128.71M | -$4.75M |
| Financing cash flow | $22.70M | $27.00M | $38.15M | $311,000 | $46.61M |
| Depreciation & amortization | $95,000 | $95,000 | $259,000 | $248,000 | $248,000 |
| Stock-based compensation | $1.40M | $319,000 | $13.73M | $17.73M | $20.79M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.